Results 61 to 70 of about 31,446 (147)

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 4, Page 573-583, August 2026.
RVD with weekly bortezomib dosing in real‐world newly diagnosed transplant‐ineligible myeloma shows comparable efficacy and reduced toxicity compared to twice‐weekly trial protocols. ABSTRACT Background Lenalidomide, bortezomib, and dexamethasone (RVD) remains a standard of care regimen for newly diagnosed multiple myeloma in centers without access to ...
Samantha Kurniawan, Angela Hwang, Nicole Wong Doo, Tracy King, Christian Bryant, Jennifer Zhang, Kristina Whelan, Parisa Fani‐Molky, Giselle Kidson‐Gerber, Annmarie Bosco, Nada Hamad, Gurdeep Parmar, Fiona Kwok, Sam Lai, Silvia Ling, P. Joy Ho, Georgia McCaughan, Adam Bryant   +17 more
wiley   +1 more source

Solicitude of Caregivers toward their Children with Guillain-Barre Syndrome [PDF]

Egyptian Journal of Health Care
Background: Guillain-Barré syndrome is the most common and severe acute paralytic neuropathy that affects all aspects of a child's life. Aim of the study was to assess solicitude of caregivers toward their children with Guillain-Barre syndrome. Method: A
Asmaa Nsr El-din Mosbeh, Sara Mohamed Atta, Safy Salah El-din Elrafey   +2 more
doaj   +1 more source

S3‐Leitlinie Diagnostik und Therapie der Alopecia areata – Teil 2: Therapie, psychosoziale und kosmetische Unterstützung

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 8, Page 1155-1179, August 2026.
Zusammenfassung In diesem zweiten Teil der S3‐Leitlinie zur Diagnostik und Therapie der Alopecia areata (AA) stellen wir die zentralen Inhalte und Empfehlungen zur topischen und systemischen Therapie, zur Lebensqualität und zu Unterstützungsangeboten vor.
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

FREQUENCY OF AXONAL VARIANTS OF GUILLAIN-BARRÉ SYNDROME IN PAKISTAN

Pakistan Armed Forces Medical Journal, 2011
Objective: To determine the frequency of axonal variants in our patients of Guillain-Barre Syndrome. Study Design: Descriptive study. Place and Duration: Department of Neurology, Military Hospital, Rawalpindi and Armed Forces Institute of Rehabilitation
Muhamamd Babar Khan, Waseem Wali Muhammad, Khuram Haq Nawaz, Imran Ahmad, Muhammad Ali Yousaf,, Nadeem Ahmad, Farooq Azam Rathore, Khalil Ahmad   +7 more
doaj   +2 more sources

A Case of Neurobrucellosis Mimicking Guillain-Barre Syndrome

مجله دانشکده پزشکی اصفهان, 2007
BACKGROUND: Brucellosis is an infectious disease due to Gram negative bacteria of genus brucella. Involvement of different systems including gastrointestinal tract, the hepatobilliary and skeletal systems has been frequently reported.
Naser Sharafoddin Zadeh, Majid Keyhani Fard   +1 more
doaj  

S3 guideline diagnostics and therapy in alopecia areata – Part 2: Therapy, psychosocial and cosmetic support

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 8, Page e1155-e1177, August 2026.
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

The Diagnostic Accuracy of the Second Revision of the European Academy of Neurology/Peripheral Nerve Society Guideline for Diagnosing Chronic Inflammatory Demyelinating Polyradiculoneuropathy

European Journal of Neurology, Volume 33, Issue 8, August 2026.
ABSTRACT Background Diagnosing chronic inflammatory demyelinating polyneuropathy (CIDP) relies on clinical and electrodiagnostic features. In 2021, the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) revised the CIDP guideline, superseding the 2010 European Federation of Neurological Societies (EFNS)/PNS guideline.
Iris N. van Doorn, Adája E. Baars, Luuk Wieske, Bart C. Jacobs, Krista Kuitwaard, W. Ludo van der Pol, Pieter A. van Doorn, Ivo N. van Schaik, Filip Eftimov, H. Stephan Goedee, Judith Drenthen, Camiel Verhamme   +11 more
wiley   +1 more source

Development of recurrent facial palsy during plasmapheresis in Guillain-Barré syndrome: a case report

Journal of Medical Case Reports, 2010
Introduction Guillain-Barré syndrome is an immune-mediated polyneuropathy that is routinely initially treated with either intravenous immunoglobulin or plasmapheresis.
Weimer Louis H, Stevenson Mary L, Bogorad Ilya V   +2 more
doaj   +1 more source

Vectors and Vector‐Borne Diseases: Biology, Epidemiology and Integrated Control Strategies

Journal of Applied Entomology, Volume 150, Issue 7, Page 990-1015, August 2026.
ABSTRACT Vector‐Borne Diseases (VBDs), transmitted by arthropods such as mosquitoes, ticks, fleas and sandflies, represent a significant threat to global health. These diseases can be caused by a variety of pathogens, including bacteria, viruses, protozoa, and helminths.
Roberta Rinaldi, Carmen Scieuzo, Federica De Stefano, Luca Masucci, Patrizia Falabella   +4 more
wiley   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.
What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source